Plus   Neg

Genentech: FDA Grants Priority Review For Risdiplam - Quick Facts

Genentech, a member of the Roche Group (RHHBY.PK), announced the U.S. FDA has accepted the New Drug Application and granted priority review for risdiplam, an investigational survival motor neuron-2 splicing modifier for spinal muscular atrophy. Previously, the FDA granted Orphan Drug Designation for risdiplam in 2017, followed by Fast Track Designation. The final FDA decision is expected by May 24, 2020.

If approved, risdiplam would be the first at-home administered medicine for people living with spinal muscular atrophy. Genentech leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics, Inc. (PTCT).

The FDA's acceptance of the NDA triggers a $15 million milestone payment to PTC by Roche.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Online-video streaming giant Netflix Inc. (NFLX), Tuesday reported a fourth-quarter profit that trounced Wall Street estimates, as revenues surged 31% driven by strong subscriber growth. Netflix added 8.76 million subscribers globally in the quarter, above its forecast of 7.60 million, to end the... Fast food chain Krystal Company has filed for bankruptcy, according to reports. The Atlanta-based Krystal filed for Chapter 11 on Sunday in the U.S. Bankruptcy Court in Atlanta. In the filing, the company reportedly disclosed assets between $10 million and $50 million, and liabilities between $50 million and $100 million. The chief executive officer of Google's parent company Alphabet called for artificial intelligence or AI to be regulated, noting that there are real concerns about the potential negative consequences of the technology. According to Alphabet CEO Sundar Pichai, there are real concerns about the negative consequences of AI, from deepfakes to nefarious uses of facial recognition.
Follow RTT